292 related articles for article (PubMed ID: 21411598)
1. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines.
Thiem VD; Lin FY; Canh DG; Son NH; Anh DD; Mao ND; Chu C; Hunt SW; Robbins JB; Schneerson R; Szu SC
Clin Vaccine Immunol; 2011 May; 18(5):730-5. PubMed ID: 21411598
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.
Kossaczka Z; Lin FY; Ho VA; Thuy NT; Van Bay P; Thanh TC; Khiem HB; Trach DD; Karpas A; Hunt S; Bryla DA; Schneerson R; Robbins JB; Szu SC
Infect Immun; 1999 Nov; 67(11):5806-10. PubMed ID: 10531232
[TBL] [Abstract][Full Text] [Related]
3. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children.
Canh DG; Lin FY; Thiem VD; Trach DD; Trong ND; Mao ND; Hunt S; Schneerson R; Robbins JB; Chu C; Shiloach J; Bryla DA; Bonnet MC; Schulz D; Szu SC
Infect Immun; 2004 Nov; 72(11):6586-8. PubMed ID: 15501790
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
[TBL] [Abstract][Full Text] [Related]
5. Development of Vi conjugate - a new generation of typhoid vaccine.
Szu SC
Expert Rev Vaccines; 2013 Nov; 12(11):1273-86. PubMed ID: 24156285
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine.
Szu SC; Lin KF; Hunt S; Chu C; Thinh ND
Vaccine; 2014 May; 32(22):2618-22. PubMed ID: 24657719
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants.
Lee CY; Thipphawong J; Huang LM; Lee PI; Chiu HH; Lin W; Debois H; Harrison D; Xie F; Barreto L
Pediatrics; 1999 Jan; 103(1):25-30. PubMed ID: 9917435
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ
Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290
[TBL] [Abstract][Full Text] [Related]
11. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
Szu SC; Klugman KP; Hunt S
Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
[TBL] [Abstract][Full Text] [Related]
13. The immunogenicity and safety of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in Gambian infants.
Mulholland EK; Byass P; Campbell H; Fritzell B; Greenwood AM; Todd J; Greenwood BM
Ann Trop Paediatr; 1994; 14(3):183-8. PubMed ID: 7825990
[TBL] [Abstract][Full Text] [Related]
14. Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.
Iro MA; Khatami A; Marshall AS; Pace D; Voysey M; McKenna J; Campbell D; Attard-Montalto S; Finn A; White C; Faust SN; Kent A; Heath PT; MacLeod E; Stanford E; Findlow H; Almond R; Bai X; Borrow R; Snape MD; Pollard AJ
Lancet Infect Dis; 2015 Feb; 15(2):172-80. PubMed ID: 25577661
[TBL] [Abstract][Full Text] [Related]
15. Effect of transplacentally acquired tetanus antibodies on the antibody responses to Haemophilus influenzae type b-tetanus toxoid conjugate and tetanus toxoid vaccines in Filipino infants.
Nohynek H; Gustafsson L; Capeding MR; Käyhty H; Olander RM; Pascualk L; Ruutu P
Pediatr Infect Dis J; 1999 Jan; 18(1):25-30. PubMed ID: 9951976
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period.
Miller MA; Meschievitz CK; Ballanco GA; Daum RS
Pediatrics; 1995 Apr; 95(4):522-7. PubMed ID: 7700752
[TBL] [Abstract][Full Text] [Related]
18. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
Cartee RT; Thanawastien A; Griffin Iv TJ; Mekalanos JJ; Bart S; Killeen KP
PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007912. PubMed ID: 31905228
[TBL] [Abstract][Full Text] [Related]
20. Suppression and modulation of cellular and humoral immune responses to Haemophilus influenzae type B (Hib) conjugate vaccine in hib-diphtheria-tetanus toxoids-acellular pertussis combination vaccines: a study in a rat model.
Mawas F; Newman G; Burns S; Corbel MJ
J Infect Dis; 2005 Jan; 191(1):58-64. PubMed ID: 15593004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]